[1]
Chiriboga C.A., Swoboda K.J., Darras B.T., et al.: Results from a phase
1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular
atrophy. Neurology 2016; 86: 890–897.
[2]
Gidaro T., Servais L.: Nusinersen treatment of spinal muscular atrophy:
current knowledge and existing gaps. Dev Med Child Neurol 2019; 61:
19–24.
[3]
Jedrzejowska M., Milewski M., Zimowski J., et al.: Incidence of
spinal muscular atrophy in Poland—more frequent than predicted?
Neuroepidemiology 2010; 34: 152–157.
[4]
Verhaart I.E.C., Robertson A., Leary R., et al.: A multi-source approach
to determine SMA incidence and research ready population. J Neurol
2017; 264: 1465–1473.
[5]
Grotto S., Cuisset J.M., Marret S., et al.: Type 0 spinal muscular atrophy:
further delineation of prenatal and postnatal features in 16 patients.
J Neuromuscul Dis 2016; 3: 487–495.
[6]
Wang C.H., Finkel R.S., Bertini E.S., et al.: Consensus statement for
standard of care in spinal muscular atrophy. J Child Neurol 2007; 22:
1027–1049.
[7]
D’Amico A., Mercuri E., Tiziano F.D., et al.: Spinal muscular atrophy.
Orphanet J Rare Dis. 2011; 6.
[8]
Finkel R.S., McDermott M.P., Kaufmann P., et al.: Observational study
of spinal muscular atrophy type I and implications for clinical trials.
Neurology 2014; 83: 810– 817.
[9]
De Sanctis R., Coratti G., Pasternak A., et al.: Developmental milestones in
type I spinal muscular atrophy. Neuromuscul Disord 2016; 26: 754–759.
[10]
Zerres K., Rudnik-Schoneborn S.: Natural history in proximal spinal
muscular atrophy. Clinical analysis of 445 patients and suggestions for
a modification of existing classifications. Arch Neurol 1995; 52: 518–523.
[11]
Mercuri E., Finkel R., Montes J., et al.: Patterns of disease progression
in type 2 and 3 SMA: Implications for clinical trials. Neuromuscul Disord
2016; 26: 126–131.
[12]
Hua Y., Sahashi K., Hung G., et al.: Antisense correction of SMN2 splicing
in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev
2010; 24: 1634–1644.
[13]
Meylemans A., De Bleecker J.: Current evidence for treatment with
nusinersen for spinal muscular atrophy: a systematic review. Acta
Neurol Belg 2019; 119: 523–533.
[14]
Chiriboga C.A.: Nusinersen for the treatment of spinal muscular atrophy.
Expert Rev Neurother 2017; 17: 955–962.
[15]
Lorson C.L., Hahnen E., Androphy E.J., et al.: A single nucleotide in the
SMN gene regulates splicing and is responsible for spinal muscular
atrophy. Proc Natl Acad Sci U S A 1999; 96: 6307–6311.
[16]
Monani U.R., Lorson C.L., Parsons D.W., et al.: A single nucleotide
difference that alters splicing patterns distinguishes the SMA gene
SMN1 from the copy gene SMN2. Hum Mol Genet 1999; 8: 1177–1183.
[17]
Kolb S.J., Kissel J.T.: Spinal muscular atrophy. Neurol Clin 2015; 33: 831–846.
[18]
Prior T.W., Swoboda K.J., Scott H.D., et al.: Homozygous SMN1 deletions
in unaffected family members and modification of the phenotype by
SMN2. Am J Med Genet A 2004; 130A: 307–310.
[19]
Prior T.W., Krainer A.R., Hua Y., et al.: A positive modifier of spinal muscular
atrophy in the SMN2 gene. Am J Hum Genet 2009; 85: 408–413.
[20]
Sugarman E.A., Nagan N., Zhu H., et al.: Pan-ethnic carrier screening
and prenatal diagnosis for spinal muscular atrophy: clinical laboratory
analysis of >72,400 specimens. Eur J Hum Genet 2012; 20: 27–32.
[21]
Mailman M.D., Heinz J.W., Papp A.C., et al.: Molecular analysis of spinal
muscular atrophy and modification of the phenotype by SMN2. Genet
Med 2002; 4: 20–26.
[22]
Crawford T.O., Paushkin S.V., Kobayashi D.T., et al.: Evaluation of SMN
protein, transcript, and copy number in the biomarkers for spinal
muscular atrophy (BforSMA) clinical study. PLoS One 2012; 7: e33572.
[23]
Finkel R.S., Chiriboga C.A., Vajsar J., et al.: Treatment of infantile-onset
spinal muscular atrophy with nusinersen: a phase 2, open-label, doseescalation
study. Lancet 2016; 388: 3017–3026.
[24]
Finkel R.S., Mercuri E., Darras B.T., et al.: Nusinersen versus sham
control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;
377:1723–1732.
[25]
Mercuri E., Darras B.T., Chiriboga C.A., et al.: Nusinersen versus sham
control in later-onset spinal muscular atrophy. N Engl J Med 2018; 378:
625–635.
[26]
Darras B.T., Farrar M.A., Mercuri E., et al.: An integrated safety analysis
of infants and children with symptomatic spinal muscular atrophy (SMA)
treated with nusinersen in seven clinical trials. CNS Drugs 2019; 33:
919–932.
, Sandra Modrzejewska2
Scholar Google
PubMed